Chemotherapy for vulval cancer
Chemotherapy is treatment with anti-cancer (cytotoxic) drugs. This may be used with radiotherapy or by itself to treat vulval cancer.
You may have chemotherapy for vulval cancer:
- To shrink the cancer before surgery or radiotherapy. This is called neo-adjuvant chemotherapy.
- After surgery to reduce the risk of cancer coming back. This is called adjuvant treatment. You may have radiotherapy at the same time (chemoradiation).
- With radiotherapy (chemoradiation) as your main treatment if surgery is not possible.
- To treat the symptoms of advanced cancer that cannot be cured. This is known as palliative treatment.
The main chemotherapy drugs used to treat vulval cancer are:
Other chemotherapy drugs may sometimes be used. Your doctor or specialist nurse will talk to you about the treatment and any possible side effects.
Medicines can usually control side effects of chemotherapy. Side effects will usually go away when treatment finishes. Not all drugs cause the same side effects, and some people may have very few. Your doctor or nurse will tell you more about what to expect. Always tell them about any side effects you have, as there are usually ways they can help.
You can usually have chemotherapy as an outpatient. Sometimes you may need to stay in hospital for a few days.
Most drugs are given into a vein (intravenously), but some can be given by mouth as tablets or capsules. Intravenous chemotherapy is a session of treatment which you have over several hours or days. You then have a rest period of a few weeks. This allows your body to recover from any side effects. The treatment and rest period make up a cycle of treatment. Your cancer specialist will tell you how many cycles of treatment you will have.
Below is a sample of the sources used in our vulval cancer information. If you would like more information about the sources we use, please contact us at firstname.lastname@example.org
Morrison J, Baldwin P, Buckley L, et al. Gynaecological Cancer Society (BGCS) vulval cancer guidelines: recommendations for practice. 2020. Available from https://www.bgcs.org.uk/wp-content/uploads/2021/07/BGCS-vulval-guidelines-v22.pdf [accessed November 2020].
Rogers LJ, and Cuello MA. Cancer of the vulva. Int J Gynaecol Obstet, 2018; 143, S2, 4-13. Available from https://doi.org/10.1002/ijgo.12609 [accessed November 2020].
This information has been written, revised and edited by Macmillan Cancer Support’s Cancer Information Development team. It has been reviewed by expert medical and health professionals and people living with cancer. It has been approved by Senior Medical Editor, Professor Nick Reed, Consultant Clinical Oncologist.
Our cancer information has been awarded the PIF TICK. Created by the Patient Information Forum, this quality mark shows we meet PIF’s 10 criteria for trustworthy health information.
The language we use
We want everyone affected by cancer to feel our information is written for them.
We try to make sure our information is as clear as possible. We use plain English, avoid jargon, explain any medical words, use illustrations to explain text, and make sure important points are highlighted clearly.
We use gender-inclusive language and talk to our readers as ‘you’ so that everyone feels included. Where clinically necessary we use the terms ‘men’ and ‘women’ or ‘male’ and ‘female’. For example, we do so when talking about parts of the body or mentioning statistics or research about who is affected. Our aims are for our information to be as clear and relevant as possible for everyone.
You can read more about how we produce our information here.